CD2 and breast cancer: Additionally, we incorporated previously published data sets of a breast cancer model (MMTV-PyMT) [44], a chemically induced colon cancer model (AOM/DSS treatment) [44], a spontaneous liver tumor model (C3H strain liver tumors) [40], two melanoma models (BrafV600E/Ptenfl/fl and BrafV600E/Ptenfl/fl/Dnmt3bfl/fl) [45], as well as a variety of acute myeloid leukemia (LAML) (Dnmt3afl/fl, Flt3-ITDKI, Flt3-ITDKI/Dnmt3afl/+, Tet2fl/fl/FLT3-ITD, Idh1(R132H)KI) [46–49] and T-ALL models (Dnmt3afl/fl, FLT3-ITD (retroviral infection), FLT3-ITD/Dnmt3afl/fl, Ptenfl/fl, CD2-Lmo2tg) [46, 47, 50].